A Phase 2, Open-Label, Single-Arm Study Evaluating the Combination of Pembrolizumab (pembro), Lenvatinib, and Chemotherapy in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harbouring a Targetable Mutation Who Experienced Disease Progression on Standard Tyrosine Kinase Inhibitors (Tkis).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined